SEOM Clinical Guidelines in Early-stage Breast Cancer 2015

Overview

Journal Clin Transl Oncol

Specialty Oncology

Date 2015 Oct 27

PMID 26497356

Citations 13

Authors

J A Garcia-Saenz

B Bermejo

L G Estevez

A G Palomo

X Gonzalez-Farre

M Margeli

S Pernas

S Servitja

C A Rodriguez

E Ciruelos

Affiliations

Soon will be listed here.

Abstract

Breast cancer is a major public health problem. Despite remarkable advances in early diagnosis and treatment, one in three women may have metastases since diagnosis. Better understanding of prognostic and predictive factors allows us to select the most appropriate adjuvant therapy in each patient. In these guidelines, we summarize current evidence for the medical management of early-stage breast cancer.

Citing Articles

Assessing the methodological strengths and limitations of the Spanish Society of Medical Oncology (SEOM) guidelines: a critical appraisal using AGREE II and AGREE-REX tool.

Santero M, de Mas J, Rifa B, Clavero I, Rexach I, Bonfill Cosp X Clin Transl Oncol. 2023; 26(1):85-97.

PMID: 37368198 PMC: 10761528. DOI: 10.1007/s12094-023-03219-0.

Benefits of neoadjuvant therapy compared with adjuvant chemotherapy for the survival of patients with HER2-positive breast cancer: A retrospective cohort study at FUSCC.

Zheng S, Li L, Chen M, Yang B, Chen J, Liu G Breast. 2022; 63:177-186.

PMID: 35429731 PMC: 9038764. DOI: 10.1016/j.breast.2022.03.015.

Review of imaging techniques for evaluating morphological and functional responses to the treatment of bone metastases in prostate and breast cancer.

Orcajo-Rincon J, Munoz-Langa J, Sepulveda-Sanchez J, Fernandez-Perez G, Martinez M, Noriega-Alvarez E Clin Transl Oncol. 2022; 24(7):1290-1310.

PMID: 35152355 PMC: 9192443. DOI: 10.1007/s12094-022-02784-0.

Mechanisms of Drug Resistance and Use of Nanoparticle Delivery to Overcome Resistance in Breast Cancers.

Beyaz H, Uludag H, Kavaz D, Rizaner N Adv Exp Med Biol. 2021; 1347:163-181.

PMID: 34287795 DOI: 10.1007/5584_2021_648.

Spatially multiplexed RNA in situ hybridization to reveal tumor heterogeneity.

Voith von Voithenberg L, Khartchenko A, Huber D, Schraml P, Kaigala G Nucleic Acids Res. 2019; 48(3):e17.

PMID: 31853536 PMC: 7026647. DOI: 10.1093/nar/gkz1151.

References

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M . A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351(27):2817-26. DOI: 10.1056/NEJMoa041588. View

Bedrosian I, Hu C, Chang G . Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients. J Natl Cancer Inst. 2010; 102(6):401-9. PMC: 4415082. DOI: 10.1093/jnci/djq018. View

Peto R, Davies C, Godwin J, Gray R, Pan H, Clarke M . Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2011; 379(9814):432-44. PMC: 3273723. DOI: 10.1016/S0140-6736(11)61625-5. View

Cho S, Jeon J, Kim S . Personalized medicine in breast cancer: a systematic review. J Breast Cancer. 2012; 15(3):265-72. PMC: 3468779. DOI: 10.4048/jbc.2012.15.3.265. View

Paik S, Tang G, Shak S, Kim C, Baker J, Kim W . Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006; 24(23):3726-34. DOI: 10.1200/JCO.2005.04.7985. View

Sikov W, Berry D, Perou C, Singh B, Cirrincione C, Tolaney S . Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB.... J Clin Oncol. 2014; 33(1):13-21. PMC: 4268249. DOI: 10.1200/JCO.2014.57.0572. View

Prat A, Galvan P, Jimenez B, Buckingham W, Jeiranian H, Schaper C . Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay. Clin Cancer Res. 2015; 22(3):560-6. DOI: 10.1158/1078-0432.CCR-15-0630. View

Dowsett M, Sestak I, Lopez-Knowles E, Sidhu K, Dunbier A, Cowens J . Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol. 2013; 31(22):2783-90. DOI: 10.1200/JCO.2012.46.1558. View

Nielsen T, Parker J, Leung S, Voduc D, Ebbert M, Vickery T . A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res. 2010; 16(21):5222-32. PMC: 2970720. DOI: 10.1158/1078-0432.CCR-10-1282. View

10.

McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M . Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014; 383(9935):2127-35. PMC: 5015598. DOI: 10.1016/S0140-6736(14)60488-8. View

11.

Gianni L, Dafni U, Gelber R, Azambuja E, Muehlbauer S, Goldhirsch A . Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol. 2011; 12(3):236-44. DOI: 10.1016/S1470-2045(11)70033-X. View

12.

Vaz-Luis I, Ottesen R, Hughes M, Mamet R, Burstein H, Edge S . Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. J Clin Oncol. 2014; 32(20):2142-50. PMC: 4076026. DOI: 10.1200/JCO.2013.53.1608. View

13.

Pagani O, Regan M, Walley B, Fleming G, Colleoni M, Lang I . Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014; 371(2):107-18. PMC: 4175521. DOI: 10.1056/NEJMoa1404037. View

14.

Alba E, Calvo L, Albanell J, De la Haba J, Arcusa Lanza A, Chacon J . Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study. Ann Oncol. 2012; 23(12):3069-3074. DOI: 10.1093/annonc/mds132. View

15.

Perez E, Romond E, Suman V, Jeong J, Sledge G, Geyer Jr C . Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014; 32(33):3744-52. PMC: 4226805. DOI: 10.1200/JCO.2014.55.5730. View

16.

Fisher B, Anderson S, Bryant J, Margolese R, Deutsch M, Fisher E . Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002; 347(16):1233-41. DOI: 10.1056/NEJMoa022152. View

17.

Tolaney S, Barry W, Dang C, Yardley D, Moy B, Marcom P . Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med. 2015; 372(2):134-41. PMC: 4313867. DOI: 10.1056/NEJMoa1406281. View

18.

Simon R, Paik S, Hayes D . Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst. 2009; 101(21):1446-52. PMC: 2782246. DOI: 10.1093/jnci/djp335. View

19.

Goldhirsch A, Gelber R, Piccart-Gebhart M, de Azambuja E, Procter M, Suter T . 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet. 2013; 382(9897):1021-8. DOI: 10.1016/S0140-6736(13)61094-6. View

20.

Sparano J, Gray R, Makower D, Pritchard K, Albain K, Hayes D . Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med. 2015; 373(21):2005-14. PMC: 4701034. DOI: 10.1056/NEJMoa1510764. View